<DOC>
	<DOCNO>NCT01541202</DOCNO>
	<brief_summary>The purpose study evaluate efficacy rhNRG-1 reduce death rate heart failure .</brief_summary>
	<brief_title>Study Survival Recombinant Human Neuregulin-1β Chronic Heart Failure ( CHF ) Patients</brief_title>
	<detailed_description>The mortality chronic heart failure patient remain high , spite current treatment . RhNRG-1 ( recombinant human neuregulin-1 ) directly work cardiomyocyte restore normal structure function . Both preclinical trial phase II clinical trail confirm rhNRG-1 effectively enhance heart function , reverse remodel left ventricular , reduce all-cause mortality heart failure animal human . In phase III study , investigator confirm efficacy rhNRG-1 reduce death rate heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age 18 75 , sex . 2 . Left ventricular ejection fraction ( LVEF ) ≤40 % ( ECHO ) . 3 . NYNA functional class II OR III . 4 . Diagnosed chronic systolic heart failure ( history , symptom , sign ) , inhospital history last one month . 5 . Receiving standard therapy chronic heart failure , reach target dose max tolerable dose one month , change dose last one month . 6 . Capable signing inform consent form . 1. new chronic heart failure patient , patient receive standard therapy chronic heart failure le 3 month . 2 . NYNA functional class I OR IV . 3 . Patients acute MI , hypertrophic cardiomyopathy , constrictive pericarditis , significant valvular pathological change congenital heart disease , primary secondary severe pulmonary artery hypertension . 4 . Ischemic heart failure without recanalization recanalization recent six month . 5. acute MI last 3 month . 6. unstable angina . 7 . Patients acute pulmonary edema acute hemodynamic disorder . 8 . Chronic heart failure patient acute hemodynamic disorder acute decompensation last 1 month . 9 . Patients right heart failure cause pulmonary disease . 10 . Patients diagnose pericardial effusion pleural effusion , evidence Btype ultrasonic ( &gt; 50ml ) . 11 . Cardiac surgery cerebrovascular accident within recent six month . 12 . Preparing heart transplantation CRT , receive CRT . 13 . Serious ventricular arrhythmia ( multimorphological premature ventricular contraction 5 times/min , frequent paroxysmal ventricular tachycardia triple rate ) . 14 . Serious hepatic renal dysfunction ( Cr＞2.0mg/dl , AST ALT 5 time normal upper limit ) . 15 . Serum potassium &lt; 3.2 mmol/L &gt; 5.5 mmol/L . 16 . Systolic blood pressure &lt; 90mmHg &gt; 160mmHg . 17 . Pregnant plan pregnant . 18 . Patients participate clinical trial recent three month . 19 . Subject life expectancy le 6 month assess investigator . 20 . Serious nervous system disease ( Alzheimer 's disease , advance Parkinsonism ) , low limb defect , deafmute . 21 . History malignancy suffer cancer , biopsy proven premalignant condition ( eg DICS cervical atypia ) . 22 . Evidence ( physical examination , CXR , ECHO test ) show active malignancy adenoidal hypertrophy neoplasm effect heart function endocrine system , eg pheochromocytoma hyperthyroidism . 23 . Judging investigator , patient could complete study adhere study requirement ( due management reason others ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>neuregulin</keyword>
	<keyword>mortality</keyword>
</DOC>